Boehringer Targets High Unmet Need With Spesolimab Filing

Could Be First EU Approved Drug For Generalized Pustular Psoriasis Flares

05 Nov 2021

• By Ayisha Sharma

Boehringer Ingelheim files spesolimab in the EU, where it is a forerunner in the race to fill the unmet need in generalized pustular psoriasis flares.

Generalized Pustular Psoriasis Presents High Unmet Need • Source: Alamy

Boehringer Ingelheim GmbH’s filing for spesolimab for generalized pustular psoriasis (GPP) flares has been accepted by the European Medicines Agency – in a first for this indication in Europe.

“What’s exciting is that we could be the first to provide a therapy that’s targeting this patient population,” global therapeutic area

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Industry Leaders Grapple With Trump’s MFN Pricing Plan

14 May 2025

• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.